### SUPPLEMENTARY INFORMATION

### Netrin-1 functions as a suppressor of bone morphogenetic protein (BMP) signaling

Ahmad Abdullah<sup> $\dagger$ ,1</sup>, Carl Herdenberg<sup> $\dagger$ ,1</sup>, and Håkan Hedman<sup>1,\*</sup>

<sup>†</sup>These authors contributed equally to the work <sup>1</sup>Department of Radiation Sciences, Umeå University, SE-90187 Umeå, Sweden

#### \*Correspondence

H. Hedman, Oncology Research Laboratory, NUS M31, SE-90185 Umeå, Sweden Tel: +46-90-785 2881 E-mail: hakan.hedman@umu.se

### SUPPLEMENTARY INFORMATION

### **Figure legends**

Supplementary Figure S1. Western blot analyses of *Ntn1*-deficient and control MEF lines. Netrin-1 expression was knocked out in wild-type MEFs or *Lrig*-null MEFs with inducible *LRIG1* or *LRIG3* alleles using CRISPR/Cas9 followed by cell cloning. Protein expression was evaluated via Western blotting using antibodies against netrin-1, the FLAG epitope present on the inducible LRIG1 and LRIG3 proteins, or actin as the loading control.
(a) Blots showing wild-type MEFs (ScA1, ScA3, ScC3, and ScD2) and *Ntn<sup>-/-</sup>;Lrig*-wild-type MEFs (G2B2, G2A2, and G2C1). (b) Blots showing LRIG1-inducible *Ntn<sup>-/-</sup>* MEFs that had not been induced (-dox) or had been induced (+dox) to express LRIG1. (c) Blots showing LRIG3-inducible *Ntn<sup>-/-</sup>* MEFs that had not been induced (-dox) or had been induced (+dox) to express LRIG3. Uncropped blots are shown in Figure S9.

### Supplementary Figure S2. Receptor levels in MEFs of different Lrig and Ntn1

**genotypes.** (a-c) Expression levels of Bmpr2, Acvr1, and Smad1 in MEFs of different *Ntn1* (*Ntn1*<sup>+/+</sup> or *Ntn1*<sup>-/-</sup>) and *Lrig* (*Lrig*-wild-type or *Lrig*-null (*Lrig1*<sup>-/-</sup>; *Lrig2*<sup>-/-</sup>; *Lrig3*<sup>-/-</sup>) genotypes analyzed by Western blotting. Graphs represent average means with standard deviations of band intensity ratios (neogenin/actin) from four *Ntn1*<sup>+/+</sup>;*Lrig*-wild-type or *Ntn1*<sup>+/+</sup>;*Lrig*-null biological replicates and three *Ntn1*<sup>-/-</sup>;*Lrig*-wild-type or *Ntn1*<sup>+/+</sup>;*Lrig*-null biological replicates that were determined with three independent experiments. (d) Representative blots of the four clones of wild-type and three clones each of *Lrig*-wild-type/*Ntn1*<sup>-/-</sup> and *Lrig*-null/*Ntn1*<sup>-/-</sup>, respectively.

Supplementary Figure S3. Lrig and netrin-1 expression levels in MEFs of different *Ntn1* and *Lrig* genotypes. (a-d) Expression of Lrig proteins in wild-type and *Ntn1*-deficient MEF lines. (a, c) Representative blots showing Lrig1 and Lrig3 expression in four clones of wild-type MEFs and three clones of *Ntn1*-deficient MEFs. (e) Representative blot showing netrin-1 expression in four clones each of wild-type and *Lrig*-null MEF lines. (b, d, f) Graphs showing the average means with standard deviations of four independent experiments. Uncropped blots are shown in Figure S10.

**Supplementary Figure S4. Full-length blots.** Shown are the full-length blots corresponding to the cropped versions shown in Figure 2.

Supplementary Figure S5. Western blot analyses of wild-type and *Neo1*-deficient MEF lines. (a) Representative blots showing the expression of neogenin, netrin-1, Lrig1, Lrig3, and actin as loading control in four clones of *Neo1* wild-type (S1, S2, S3, and S4) and *Neo1*-deficient (1A1, 1B1, 1B2, and 2C4) MEF lines. Uncropped blots are shown in Figure S11. (b-d) Graphs representing average means with standard deviations for the expression of Lrig1, Lrig3, and netrin-1 in *Neo1* wild-type and *Neo1*-deficient MEF lines from four biological repeats. (e) Neogenin expression in wild-type MEFs treated or not treated with 10 ng/ml

BMP4 for 60 minutes. Shown are the average means and standard deviations from four independent experiments.

**Supplementary Figure S6. Neogenin levels in LRIG1- and LRIG3-inducible** *Ntn1***deficient MEFs.** Effects of induced expression of LRIG1 (**a**) and LRIG3 (**b**) on neogenin expression levels in *Ntn1*-deficient MEFs. LRIG expression was induced through the treatment of LRIG-inducible MEFs with 100 ng/ml doxycycline overnight. Neogenin and actin levels were analyzed using Western blotting. Representative blots and graphs representing average means with standard deviations of four independent experiments are shown. (Student's t-test; \*\*\*, p<0.001). Uncropped blots are shown in Figure S12.

**Supplementary Figure S7. Full-length blots.** Shown are the full-length blots corresponding to the cropped versions shown in Figure 3. Red squares indicate the parts that were displayed in Figure 3.

Supplementary Figure S8. Netrin-1 and noggin inhibit BMP4-induced ATDC5 cell chondrogenesis. ATDC5 cells were treated with (a) different concentrations of BMP4 in the absence or presence of netrin-1 (0.25  $\mu$ g/ml) or noggin (10 ng/ml), or (b) different concentrations of noggin in the absence or presence of BMP4 (5 ng/ml) for 72 hours. Thereafter, chondrogenesis was assessed via an alkaline phosphatase (ALP) assay. Graphs represent the average means with standard deviations from four independent experiments. One-way ANOVA: ####, p<0.0001.

**Supplementary Figure S9. Full-length blots.** Shown are the full-length blots corresponding to the cropped versions shown in Figure S1. Red squares indicate the parts that were displayed in Figure S1.

**Supplementary Figure S10. Full-length blots.** Shown are the full-length blots corresponding to the cropped versions shown in Figure S3. Red squares indicate the parts that were displayed in Figure S3.

**Supplementary Figure S11. Full-length blots.** Shown are the full-length blots corresponding to the cropped versions shown in Figure S5. Red squares indicate the parts that were displayed in Figure S5.

**Supplementary Figure S12. Full-length blots.** Shown are the full-length blots corresponding to the cropped versions shown in Figure S6. Red squares indicate the parts that were displayed in Figure S6.

### SUPPLEMENTARY INFORMATION

### Tables

Antigen and antibody conjugate	Host	Company	Catalog no.	Lot no.	Application <sup>a</sup>	Dilution
Netrin-1	Rabbit	Abcam	ab126729	GR250605- 25	WB	1:1,000
Neogenin	Rabbit	Novus Biologicals	NBP1- 89651	A91773	WB	1:1,000
Bmpr2	Mouse	Fisher Scientific	3F6 F8	td269789	WB	1:500
ACVR1	Rabbit	Novus Biologicals	NBP1- 33500	40142	WB	1:500
Smad1	Rabbit	Cell Signaling Technology	6944S	5	WB	1:1,000
Actin	Mouse	Cell Signaling Technology	3700	17	WB	1:5,000
pSmad1/5	Rabbit	Cell Signaling Technology	9516	9	WB, ICC	1:1,000 (WB), 1:800 (ICC)
FLAG M2	Mouse	Sigma- Aldrich	F3165	SLBN8915 V	WB, ICC	1:20,000 (WB),1:2,000 (ICC)
Mouse IgG IRDye 800CW	Goat	LI-COR Biosciences	926-32210	C81106-03	WB	1:15,000
Rabbit IgG IRDye 680RD	Goat	LI-COR Biosciences	925-68071	C60606-01	WB	1:15,000
Alexa fluor anti- rabbit 647	Goat	Invitrogen	A21245	2098544	ICC	1:1,000
Alexa fluor anti- mouse 488	Donkey	Invitrogen	A21202	13053	ICC	1:1,000

### Table S1. Antibodies used in the study.

<sup>a</sup>WB, Western blotting; ICC, immunocytochemistry





























d







е



























Actin







Actin	3				-
		_	_		
, L				-	1.17